These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 12083948)

  • 1. Gene therapy for Parkinson's disease: current status and future potential.
    Segovia J
    Am J Pharmacogenomics; 2002; 2(2):135-46. PubMed ID: 12083948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gene therapy for Parkinson's disease].
    Fraix V
    Rev Med Interne; 2004 Jul; 25(7):524-7. PubMed ID: 15219371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GDNF family ligands: a potential future for Parkinson's disease therapy.
    Mickiewicz AL; Kordower JH
    CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):703-11. PubMed ID: 21838676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising therapeutic agents for the treatment of Parkinson's disease.
    Majláth Z; Török N; Toldi J; Vécsei L
    Expert Opin Biol Ther; 2016 Jun; 16(6):787-99. PubMed ID: 26961515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomaterials in the treatment of Parkinson's disease.
    Krishnan UM
    Neurochem Int; 2021 May; 145():105003. PubMed ID: 33657427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral vectors for gene therapy in Parkinson's disease.
    Latchman DS; Coffin RS
    Rev Neurosci; 2001; 12(1):69-78. PubMed ID: 11236066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem cell treatment for Parkinson's disease: an update for 2005.
    Snyder BJ; Olanow CW
    Curr Opin Neurol; 2005 Aug; 18(4):376-85. PubMed ID: 16003112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapies in the pharmacological treatment of Parkinson's disease.
    Korczyn AD; Nussbaum M
    Drugs; 2002; 62(5):775-86. PubMed ID: 11929331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regenerative medicine for Parkinson's disease.
    Yasuhara T; Kameda M; Agari T; Date I
    Neurol Med Chir (Tokyo); 2015; 55(2):113-23. PubMed ID: 25746305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for Parkinson's disease.
    Yasuhara T; Date I
    J Neural Transm Suppl; 2009; (73):301-9. PubMed ID: 20411788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson's disease.
    Hernandez-Chan NG; Bannon MJ; Orozco-Barrios CE; Escobedo L; Zamudio S; De la Cruz F; Gongora-Alfaro JL; Armendáriz-Borunda J; Reyes-Corona D; Espadas-Alvarez AJ; Flores-Martínez YM; Ayala-Davila J; Hernandez-Gutierrez ME; Pavón L; García-Villegas R; Nadella R; Martinez-Fong D
    J Biomed Sci; 2015 Jul; 22(1):59. PubMed ID: 26198255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.
    Douglas MR
    Expert Rev Neurother; 2013 Jun; 13(6):695-705. PubMed ID: 23739006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects for new restorative and neuroprotective treatments in Parkinson's disease.
    Dunnett SB; Björklund A
    Nature; 1999 Jun; 399(6738 Suppl):A32-9. PubMed ID: 10392578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological treatments of Parkinson's disease].
    Nomoto M; Iwata S; Kaseda S
    Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):111-22. PubMed ID: 11233302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene transfer techniques for the delivery of GDNF in Parkinson's disease.
    Ridet JL; Déglon N; Aebischer P
    Novartis Found Symp; 2000; 231():202-15; discussion 215-9, 302-6. PubMed ID: 11131539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapies for Parkinson's disease.
    Djaldetti R; Melamed E
    J Neurol; 2001 May; 248(5):357-62. PubMed ID: 11437155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polylysine-modified polyethylenimine (PEI-PLL) mediated VEGF gene delivery protects dopaminergic neurons in cell culture and in rat models of Parkinson's Disease (PD).
    Sheikh MA; Malik YS; Xing Z; Guo Z; Tian H; Zhu X; Chen X
    Acta Biomater; 2017 May; 54():58-68. PubMed ID: 28025049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.